The observations suggest that monitoring and prevention of cardiovascular disease in patients with primary Sjögren's syndrome should be considered, and that Ro/SSA and La/SSB autoantibodies may be used as biomarkers to identify the group of patients with the greater need. This evidence concerns the gene SSB and Sjogren syndrome.